Literature DB >> 22952220

Why RECIST works and why it should stay--reply to counterpoint.

Manish R Sharma1, Michael L Maitland, Mark J Ratain.   

Abstract

Mesh：

Year:  2012        PMID： 22952220     DOI： 10.1158/0008-5472.CAN-12-1988

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer.

Authors:  James L Chen; Daniel E Appelbaum; Masha Kocherginsky; Charles L Cowey; Wendy Kimryn Rathmell; David F McDermott; Walter M Stadler
Journal:  Cancer Med       Date:  2013-07-10       Impact factor: 4.452

2.  Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer.

Authors:  Michael L Maitland; Matthew R Levine; Mario E Lacouture; Kristen E Wroblewski; Christine H Chung; Ilyssa O Gordon; Livia Szeto; Gail Ratko; Keyoumars Soltani; Mark F Kozloff; Philip C Hoffman; Ravi Salgia; David P Carbone; Theodore G Karrison; Everett E Vokes
Journal:  BMC Cancer       Date:  2014-01-04       Impact factor: 4.430

3.  Comparing the Efficacy of Cancer Therapies between Subgroups in Basket Trials.

Authors:  Adam C Palmer; Deborah Plana; Peter K Sorger
Journal:  Cell Syst       Date:  2020-11-18       Impact factor: 10.304
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.